Asset
Ebribafusp Alfa
Akebia Therapeutics Inc. Common Stock
Revenue
No revenue reported in loaded filings.
Clinical trials (1)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT06419205 | phase2 | recruiting | 2026-07-30 | 2028-02-01 | Akebia Therapeutics | A Phase 2 Study to Evaluate the Safety, PD, PK, and Clinical Activity of ADX-097 in Participants With IgAN, LN or C3G |
FDA applications (0)
This company has no applications containing this asset.